Psychedelic Therapy for Anxiety
Anxiety disorders — including generalized anxiety, social anxiety, and end-of-life anxiety — are being studied across multiple psychedelic substances. Definium Therapeutics' LSD analogue MM-120 showed strong Phase 2 results for generalized anxiety disorder. Psilocybin shows particular promise for existential anxiety in cancer patients, with landmark trials at NYU and Johns Hopkins demonstrating rapid and lasting relief.
Unlike traditional anxiolytics that require ongoing daily use, psychedelic-assisted therapy aims to address anxiety at a psychological root level. Researchers hypothesize that the altered state allows patients to reprocess fear responses and gain new perspectives on anxiety-provoking situations.
Clinical Trials
10 trials currently recruiting
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
University of Washington
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
Definium Therapeutics US, Inc.
A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)
Definium Therapeutics US, Inc.
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
Cybin IRL Limited
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease
Joshua Woolley, MD, PhD
A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health
Field Trip Health
Companies & Research
Organizations with active anxiety research programs